Aroa Biosurgery (ARX) | Quarterly Report

Financial Highlights

• 01 Positive cash flows from operations of NZ$1.2 million. The first quarter of positive cashflow since admission to the ASX in July 2020.
• 02 Net cash outflow from investing activities was NZ$0.8 million, reflecting routine capex.
• 03 Strong cash receipts of NZ$19.5 million.
• 04 NZ$0.3 million increase in cash on hand with strong cash
  balance of NZ$21.9 million.

Operational Highlights

• 01 46% YOY growth in Myriad sales, with AROA Direct sales now making up 56% of overall sales mix.
• 02 Largest prospective study of lower extremity reconstructions using a dermal substitute. Tissue fill and coverage achieved in 30 days with no infections or complications and just one application of Myriad .
• 03 Regulatory approval for Endoform and Myriad Matrix in Lebanon, Endoform in Vietnam, and Myriad in Saudi Arabia.